Literature DB >> 28748555

Digitalis use and lung cancer risk by histological type in men.

Wentao Li1,2, Shao-Hua Xie1, Lap-Ah Tse2, Jesper Lagergren1,3.   

Abstract

Lung cancer risk and tumor characteristics differ between sexes. Estrogen has been suggested to counteract lung cancer development. We aimed to test the hypothesis that digitalis use decreases lung cancer risk due to its estrogenic and other anticancer properties in men. This was a nationwide Swedish population-based cohort study between July 1, 2005 and December 31, 2013. Data on the use of digitalis and organic nitrates in all male individuals were derived from the Swedish Prescribed Drug Registry. New lung cancer diagnoses among cohort participants were identified from the Swedish Cancer Registry. Cox proportional hazards regression was employed to estimate hazard ratios (HRs) with 95% confidence intervals (CIs) of lung cancer in digitalis users (exposed participants) compared to users of organic nitrates without digitalis medication (unexposed participants). The study cohort contained 74,437 digitalis users and 297,301 organic nitrates users. Long-term use (≥2 years) of digitalis was associated with decreased HRs of total lung cancer (HR 0.55, 95% CI 0.39-0.79) and squamous cell carcinoma (HR 0.40, 95% CI 0.19-0.87). This large and population-based study suggests decreased risks of lung cancer overall and squamous cell carcinoma associated with long-term use of digitalis in men.
© 2017 UICC.

Entities:  

Keywords:  chemoprevention; digitalis; estrogen; incidence; lung cancer

Mesh:

Substances:

Year:  2017        PMID: 28748555     DOI: 10.1002/ijc.30908

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  2 in total

1.  Cancer mortality does not differ by antiarrhythmic drug use: A population-based cohort of Finnish men.

Authors:  Kalle J Kaapu; Lauri Rantaniemi; Kirsi Talala; Kimmo Taari; Teuvo L J Tammela; Anssi Auvinen; Teemu J Murtola
Journal:  Sci Rep       Date:  2018-07-09       Impact factor: 4.379

2.  Cohort profile: the Swedish Prescribed Drugs and Health Cohort (SPREDH).

Authors:  Shao-Hua Xie; Giola Santoni; Fredrik Mattsson; Eivind Ness-Jensen; Jesper Lagergren
Journal:  BMJ Open       Date:  2019-01-28       Impact factor: 2.692

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.